NCCN® & AstraZeneca Seeking Letters of Intent from NCCN Members for Lung Cancer care Improvement Processes

Global biopharmaceutical company AstraZeneca has formed a partnership with the National Comprehensive Cancer Network® Oncology Research Program seeking proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer (NSCLC). The collaborative partnership is inviting researchers from NCCN’s 28 member institutions to submit a letter of intent by July 9 2019. The team notes all funded programs must:

Promote evidence-based care
Be sustainable after the award funding is complete
Collect data and report outcomes
Aim to enhance clinical outcomes, patient satisfaction, or provider satisfaction
Address patient variability
Promote administrative and system efficiency

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee